Glenmark Dermatology

Glenmark is committed to developing medicines to help treat skin conditions including acne. We recognise the significant burden these
conditions place on patients’ daily lives. Access to medicines designed to treat these conditions can contribute to improving both the
physical and psychological effects they have on patients.¹

Acne

Prevalence

Acne (its full medical name is acne vulgaris) is very common, particularly in adolescents, around 80-95% of whom have acne.^2,3
It usually starts during puberty and most people will experience some form of acne in their lifetime.⁴ For most people, acne goes
away by their twenties, but it can last longer.⁴ Some people develop acne for the first time in their late twenties and beyond.⁴

Causes and symptoms

Acne is caused by a combination of factors. Sebaceous (oil-producing) glands near the surface of the skin are particularly sensitive
to androgen hormones, causing the glands to produce too much oil (sebum).^5,6 This can lead to thickening of the skin pores and
a build-up of dead skin that blocks the pores.^4,5 The mixture of the oil and dead skin cells plugging the pores produces blackheads
and whiteheads.^5,6

The build-up of oil on the skin also creates an ideal environment for bacteria to multiply and cause inflammation, causing red, swollen
or pus-filled spots (papules, pustules, nodules or cysts).^5,6

Burden

Because acne is chronic and can also lead to scarring of the skin, it often causes significant physical, social and psychological burdens.¹
People with acne may experience emotional distress, low self-esteem, poor body image, anxiety and depression, social withdrawal and
family and relationship problems.^1,7,8

Useful links

Acne can be challenging to live with, but there is plenty of support available. Here are some links to a few useful UK sites:

NHS website acne information
British Skin Foundation
British Association of Dermatologists

Report Adverse Events

Glenmark is committed to patient safety. The aim of Pharmacovigilance is to protect public health by identifying, evaluating
and minimizing safety issues in all possible ways throughout the products’ lifecycles, from discovery and research to
post-approval, when they become available to patients.

We encourage consumers, healthcare professionals, our employees and others to report adverse events (medication side
effects) to our Pharmacovigilance department.

If you would like to report an adverse event, please click here. To ask any questions about Glenmark products in the United Kingdom, please contact Glenmark Medical Information at medical_information@glenmarkpharma.com.

References: 1. Layton AM, et al. Br J Dermatol. 2021;184(2):219-225. 2. Purdy S and DeBerker D. BMJ Clin Evid. 2008;1714. 3. Zouboulis C and Bettoli V. Br J Dermatol. 2015;Suppl 1:27-36. 4. British Skin Foundation. Acne. Available at: https://knowyourskin.britishskinfoundation.org.uk/condition/acne/. Accessed April 2026. 5. Del Rosso JQ, et al. J Drugs
Dermatol. 2020;19(3):30-35. 6. Ceruti JM, et al. Mol Cell Endocrin. 2018;465:122-133. 7. Hughes O, et al. Br J Dermatol. 2023;189(Suppl 1):i11-i16. 8. Morshed ASM, et al. Sci Rep.
2023;13:21084.